BREAST CANCER

Presenters at the 2022 San Antonio Breast Cancer Symposium discussed how antibody-drug conjugates have been changing the treatment landscape for patients with breast cancer.

In a review of disparities among African American women with breast cancer, researchers found that the make-up of their tumor microenvironment leads to advanced diseases like triple-negative breast cancer.

In a study examining racial disparities, differences in curative intent, endocrine and/or chemotherapy, frequency and types of treatment-related adverse events, and more were seen in Non-Hispanic Black women vs Non-Hispanic White women with breast cancer.

During a Targeted Oncology case-based roundtable event, Aditya Bardia, MD, MPH, discussed the data supporting the use of sacituzumab govitecan in patients with triple-negative breast cancer.

Positive findings from the phase 3 TROPiCS-02 study have led to the FDA approval of sacituzumab govitecan-hziy for another indication.

Positive data from 2 phase 2 studies, SUMMIT and MutHER, have led to the addition of neratinib as a monotherapy or in combination to the National Comprehensive Cancer Network Guidelines for patients with breast cancer.

The Guardant360 CDx, which will identify patients with advanced or metastatic breast cancer who have ESR1 mutations and may benefit from elacestrant, is the fifth test to be approved by the FDA and first for patients with breast cancer.

Recent updates to clinical care for patients with ER-positive disease include the emergence of breast cancer subtypes, oral selective estrogen receptor degraders, and other oral targeted therapies.

In a cohort of 7 patients with ER+ breast cancer, treatment with zotatifin in combination with fulvestrant and abemaciclib led to 2 partial responses and and additional patient with stable disease continuing beyond 24 weeks.

The investigational drug, CFI-402257, has earned the FDA’s attention for promising preclinical results, and is now under investigation in a phase 1 study.

Starting with the PRESERVE 1 trial of patients with metastatic colorectal cancer, 5 pivotal trials evaluating trilaciclib will announce results in 2023.

During a Targeted Oncology Evolving Paradigms roundtable, Sara A. Hurvitz, MD, discussed elacestrant and other investigational agents for patients with breast cancer.

The generation in development offers reasons for excitement about improved outcomes for patients with breast cancer.

VIKTORIA-1 is a phase 3 study evaluating treatment with gedatolisib plus fulvestrant with or without palbociclib in patients with HR-positive, HER-negative breast cancer.

At a live virtual event, Priyanka Sharma, MD, discussed the treatment options for patients with metastatic breast cancer who develop triple-negative breast cancer.

Early results from the TROPION-PanTumor01 demonstrate the potential of achieving durable response with datopotamab deruxtecan while maintaining tolerability in patients with hormone receptor-positive or HER2-negative breast cancer.

Results from the GeparOLA study show that neoadjuvant olaparib did not achieved better efficacy compared with carboplatin and paclitaxel in patients with HER2-negative early breast cancer with homologous recombination deficiency.

Survival advantage was shown in a phase 3 study of neoadjuvant chemotherapy/carboplatin in patient with triple negative breast cancer.

Improvement in progression-free and overall survival was shown with sacituzumab govitecan in the phase 3 TROPiCS-02 trial.

Longer follow-up in the phase 3 STIC CTC trial substantiates that the CTC-based choice is safe in patients with metastatic breast cancer, according to investigators.

Patients with ER-positive/HER2-negative metastatic breast cancer demonstrated improvement in progression-free survival when administered elacestrant vs standard of endocrine therapy.

Treatment with various camizestrant monotherapy doses lead to survival benefit compared with fulvestrant in a post-menopausal patient population diagnosed with estrogen receptor–positive, HER2-negative advanced breast cancer.

The combination of palbociclib and fulvestrant beyond progression on prior CDK4/6 inhibitor did not show significant improvements in progression-free survival compared with fulvestrant alone in ER-positive/HER2-negative breast cancer.

Results from the VERITAC trial presented at the 2022 San Antonio Breast Cancer Symposium showed that ARV-471 monotherapy may be active in ER-positive/HER2-negative locally advanced/metastatic breast cancer.

Findings from the phase 3 CAPItello-291 trial show that the combination of capivasertib plus fulvestrant achieved improvement in progression-free survival among patients with hormone-receptor–positive/HER2-negative advanced breast cancer.